<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd">
<PubmedArticleSet>
<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">10217534</PMID>
        <DateCompleted>
            <Year>1999</Year>
            <Month>06</Month>
            <Day>22</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2018</Year>
            <Month>11</Month>
            <Day>13</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0007-1188</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>126</Volume>
                    <Issue>6</Issue>
                    <PubDate>
                        <Year>1999</Year>
                        <Month>Mar</Month>
                    </PubDate>
                </JournalIssue>
                <Title>British journal of pharmacology</Title>
                <ISOAbbreviation>Br. J. Pharmacol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Cellular disposition of sulphamethoxazole and its metabolites: implications for hypersensitivity.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1393-407</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>1. Bioactivation of sulphamethoxazole (SMX) to chemically-reactive metabolites and subsequent protein conjugation is thought to be involved in SMX hypersensitivity. We have therefore examined the cellular metabolism, disposition and conjugation of SMX and its metabolites in vitro. 2. Flow cytometry revealed binding of N-hydroxy (SMX-NHOH) and nitroso (SMX-NO) metabolites of SMX, but not of SMX itself, to the surface of viable white blood cells. Cellular haptenation by SMX-NO was reduced by exogenous glutathione (GSH). 3. SMX-NHOH and SMX-NO were rapidly reduced back to the parent compound by cysteine (CYS), GSH, human peripheral blood cells and plasma, suggesting that this is an important and ubiquitous bioinactivation mechanism. 4. Fluorescence HPLC showed that SMX-NHOH and SMX-NO depleted CYS and GSH in buffer, and to a lesser extent, in cells and plasma. 5. Neutrophil apoptosis and inhibition of neutrophil function were induced at lower concentrations of SMX-NHOH and SMX-NO than those inducing loss of membrane viability, with SMX having no effect. Lymphocytes were significantly (P&lt;0.05) more sensitive to the direct cytotoxic effects of SMX-NO than neutrophils. 6. Partitioning of SMX-NHOH into red blood cells was significantly (P&lt;0.05) lower than with the hydroxylamine of dapsone. 7. Our results suggest that the balance between oxidation of SMX to its toxic metabolites and their reduction is an important protective cellular mechanism. If an imbalance exists, haptenation of the toxic metabolites to bodily proteins including the surface of viable cells can occur, and may result in drug hypersensitivity.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Naisbitt</LastName>
                    <ForeName>D J</ForeName>
                    <Initials>DJ</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pharmacology and Therapeutics, The University of Liverpool, Merseyside.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hough</LastName>
                    <ForeName>S J</ForeName>
                    <Initials>SJ</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gill</LastName>
                    <ForeName>H J</ForeName>
                    <Initials>HJ</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Pirmohamed</LastName>
                    <ForeName>M</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kitteringham</LastName>
                    <ForeName>N R</ForeName>
                    <Initials>NR</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Park</LastName>
                    <ForeName>B K</ForeName>
                    <Initials>BK</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <Agency>Wellcome Trust</Agency>
                    <Country>United Kingdom</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Br J Pharmacol</MedlineTA>
            <NlmUniqueID>7502536</NlmUniqueID>
            <ISSNLinking>0007-1188</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000890">Anti-Infective Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D004791">Enzyme Inhibitors</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D006241">Haptens</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D016328">NF-kappa B</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D012709">Serum Albumin</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D018808">Transcription Factor AP-1</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>7QID3E7BG7</RegistryNumber>
                <NameOfSubstance UI="D001728">Dicumarol</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>968JJ8C9DV</RegistryNumber>
                <NameOfSubstance UI="D019810">Sodium Azide</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>GAN16C9B8O</RegistryNumber>
                <NameOfSubstance UI="D005978">Glutathione</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>JE42381TNV</RegistryNumber>
                <NameOfSubstance UI="D013420">Sulfamethoxazole</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>K848JZ4886</RegistryNumber>
                <NameOfSubstance UI="D003545">Cysteine</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Immunol. 1995 May 1;154(9):4719-25</RefSource>
                <PMID Version="1">7722324</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Chem Res Toxicol. 1998 Sep;11(9):969-88</RefSource>
                <PMID Version="1">9760271</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Immunopharmacol Immunotoxicol. 1995 Feb;17(1):201-13</RefSource>
                <PMID Version="1">7759772</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Bacteriol. 1995 Jul;177(13):3837-42</RefSource>
                <PMID Version="1">7601851</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Immunol. 1995 Jul 1;155(1):462-72</RefSource>
                <PMID Version="1">7602118</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Drug Metab Dispos. 1995 Mar;23(3):406-14</RefSource>
                <PMID Version="1">7628308</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Chem Res Toxicol. 1995 Jul-Aug;8(5):780-91</RefSource>
                <PMID Version="1">7548762</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>AIDS Clin Rev. 1995-1996;:65-97</RefSource>
                <PMID Version="1">7488561</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Immunol. 1996 May 15;156(10):3986-92</RefSource>
                <PMID Version="1">8621940</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Clin Pharmacol Ther. 1996 Mar;59(3):332-40</RefSource>
                <PMID Version="1">8653996</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Biochem Pharmacol. 1996 Aug 9;52(3):401-6</RefSource>
                <PMID Version="1">8687493</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Eur J Clin Invest. 1996 Jan;26(1):38-44</RefSource>
                <PMID Version="1">8682153</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>AIDS. 1996 May;10(5):501-7</RefSource>
                <PMID Version="1">8724041</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Lancet. 1996 Sep 7;348(9028):659-63</RefSource>
                <PMID Version="1">8782758</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Res Commun Mol Pathol Pharmacol. 1996 Jun;92(3):259-73</RefSource>
                <PMID Version="1">8827825</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Chem Res Toxicol. 1996 Mar;9(2):500-7</RefSource>
                <PMID Version="1">8839055</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Br J Clin Pharmacol. 1996 Sep;42(3):347-53</RefSource>
                <PMID Version="1">8877026</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Adverse Drug React Toxicol Rev. 1996 Mar;15(1):9-50</RefSource>
                <PMID Version="1">8920632</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Leukoc Biol. 1996 Nov;60(5):611-8</RefSource>
                <PMID Version="1">8929552</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Leukoc Biol. 1996 Nov;60(5):625-32</RefSource>
                <PMID Version="1">8929554</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Pharmacol Exp Ther. 1997 Feb;280(2):884-93</RefSource>
                <PMID Version="1">9023303</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Int Arch Allergy Appl Immunol. 1978;57(2):114-25</RefSource>
                <PMID Version="1">305898</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Biochem. 1980 Sep;88(3):859-69</RefSource>
                <PMID Version="1">6998978</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Biochem. 1980 Oct;88(4):1141-50</RefSource>
                <PMID Version="1">7005210</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Pathol Annu. 1982;17 Pt 2:229-59</RefSource>
                <PMID Version="1">7182752</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Antimicrob Chemother. 1986 Apr;17(4):489-98</RefSource>
                <PMID Version="1">3710957</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Ann Intern Med. 1986 Aug;105(2):179-84</RefSource>
                <PMID Version="1">3729200</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Pharmacol Exp Ther. 1986 Sep;238(3):1045-54</RefSource>
                <PMID Version="1">3746658</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Biochem Biophys Methods. 1986 Nov;13(4-5):231-49</RefSource>
                <PMID Version="1">3805576</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Pharmacol Exp Ther. 1988 Feb;244(2):724-8</RefSource>
                <PMID Version="1">3346843</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Ann Intern Med. 1989 Feb 15;110(4):286-9</RefSource>
                <PMID Version="1">2913915</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Biol Chem Hoppe Seyler. 1989 Feb;370(2):101-8</RefSource>
                <PMID Version="1">2784973</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Biochim Biophys Acta. 1990 Mar 12;1043(1):52-6</RefSource>
                <PMID Version="1">2155662</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Mol Pharmacol. 1990 Nov;38(5):744-51</RefSource>
                <PMID Version="1">2172779</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Immunol Methods. 1991 Jun 3;139(2):271-9</RefSource>
                <PMID Version="1">1710634</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Biochim Biophys Acta. 1991 Dec 10;1072(2-3):129-57</RefSource>
                <PMID Version="1">1751545</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Chem Res Toxicol. 1989 May-Jun;2(3):186-92</RefSource>
                <PMID Version="1">2562421</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Br J Clin Pharmacol. 1991 Sep;32(3):303-10</RefSource>
                <PMID Version="1">1685664</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Drug Metab Dispos. 1991 Sep-Oct;19(5):900-6</RefSource>
                <PMID Version="1">1686233</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Lancet. 1992 Apr 11;339(8798):909-12</RefSource>
                <PMID Version="1">1348307</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Chem Biol Interact. 1992 Apr 15;82(2):151-63</RefSource>
                <PMID Version="1">1568267</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Am Acad Dermatol. 1992 Apr;26(4):567-74</RefSource>
                <PMID Version="1">1597543</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Drug Metab Rev. 1992;24(3):299-366</RefSource>
                <PMID Version="1">1628536</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Chem Biol Interact. 1992 Sep 28;84(2):169-88</RefSource>
                <PMID Version="1">1394622</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Clin Pharmacol Ther. 1993 May;53(5):529-35</RefSource>
                <PMID Version="1">8491064</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Br J Clin Pharmacol. 1993 Jul;36(1):31-8</RefSource>
                <PMID Version="1">8373710</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Clin Exp Immunol. 1993 Oct;94(1):21-5</RefSource>
                <PMID Version="1">8403509</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Arch Intern Med. 1994 May 9;154(9):949-73</RefSource>
                <PMID Version="1">8179453</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Annu Rev Immunol. 1994;12:141-79</RefSource>
                <PMID Version="1">8011280</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Allergy Clin Immunol. 1994 Dec;94(6 Pt 1):1017-24</RefSource>
                <PMID Version="1">7798534</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Toxicology. 1995 Jan 6;95(1-3):141-6</RefSource>
                <PMID Version="1">7825180</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Acquir Immune Defic Syndr Hum Retrovirol. 1995 Feb 1;8(2):134-40</RefSource>
                <PMID Version="1">7834397</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Br J Dermatol. 1995 Feb;132(2):257-62</RefSource>
                <PMID Version="1">7888363</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Clin Diagn Lab Immunol. 1995 Mar;2(2):199-204</RefSource>
                <PMID Version="1">7697529</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Inflamm. 1995-1996;47(3):138-50</RefSource>
                <PMID Version="1">9117441</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Methods Find Exp Clin Pharmacol. 1997 Mar;19(2):129-32</RefSource>
                <PMID Version="1">9151289</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Clin Invest. 1997 Jul 1;100(1):136-41</RefSource>
                <PMID Version="1">9202065</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Pharmacol Exp Ther. 1997 Aug;282(2):795-801</RefSource>
                <PMID Version="1">9262343</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>AIDS. 1997 Nov 15;11(14):1689-97</RefSource>
                <PMID Version="1">9386803</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Pharmacol Ther. 1997 Sep;75(3):153-77</RefSource>
                <PMID Version="1">9504137</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>AIDS. 1995 Mar;9(3):217-22</RefSource>
                <PMID Version="1">7755908</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000890" MajorTopicYN="N">Anti-Infective Agents</DescriptorName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
                <QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D002417" MajorTopicYN="N">Cattle</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D003545" MajorTopicYN="N">Cysteine</DescriptorName>
                <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D001728" MajorTopicYN="N">Dicumarol</DescriptorName>
                <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004342" MajorTopicYN="N">Drug Hypersensitivity</DescriptorName>
                <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004791" MajorTopicYN="N">Enzyme Inhibitors</DescriptorName>
                <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004912" MajorTopicYN="N">Erythrocytes</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005434" MajorTopicYN="N">Flow Cytometry</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005978" MajorTopicYN="N">Glutathione</DescriptorName>
                <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006241" MajorTopicYN="N">Haptens</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007963" MajorTopicYN="N">Leukocytes, Mononuclear</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008214" MajorTopicYN="N">Lymphocytes</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016328" MajorTopicYN="N">NF-kappa B</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009504" MajorTopicYN="N">Neutrophils</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D010084" MajorTopicYN="N">Oxidation-Reduction</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011485" MajorTopicYN="N">Protein Binding</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012709" MajorTopicYN="N">Serum Albumin</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019810" MajorTopicYN="N">Sodium Azide</DescriptorName>
                <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D013420" MajorTopicYN="N">Sulfamethoxazole</DescriptorName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
                <QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D018808" MajorTopicYN="N">Transcription Factor AP-1</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1999</Year>
                <Month>4</Month>
                <Day>27</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>1999</Year>
                <Month>4</Month>
                <Day>27</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1999</Year>
                <Month>4</Month>
                <Day>27</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">10217534</ArticleId>
            <ArticleId IdType="doi">10.1038/sj.bjp.0702453</ArticleId>
            <ArticleId IdType="pmc">PMC1565922</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>

</PubmedArticleSet>
